Dr. Thomas Kepczyk, M.D.
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- Medical school
- University of Arizona College of Medicine (1986)
- Years since graduation
- 40
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 781
Licensed in Texas since 1995, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1986Medical school: University of Arizona College of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
TX license J8010 (first issued 1995; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Christus Santa Rosa Hospital-San Marcos San Marcos, TX
- Guadalupe Regional Medical Center Seguin, TX
- Resolute Health Hospital New Braunfels, TX
Medical groups
- Texas Digestive Disease Consultants, PLLC (608 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 781
- Services billed
- 8,891
- Patients’ average age
- 74
| Service | Times | Patients |
|---|---|---|
| Removal of polyps or growths of large bowel using an endoscope with mechanical snare | 189 | 189 |
| Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | 188 | 180 |
| Established patient office or other outpatient visit, 30-39 minutes | 176 | 160 |
| Biopsy of large bowel using a flexible endoscope | 170 | 170 |
| Established patient office or other outpatient visit, 20-29 minutes | 156 | 142 |
| New patient office or other outpatient visit, 45-59 minutes | 66 | 66 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 50 | 29 |
| Colorectal cancer screening; colonoscopy on individual at high risk | 47 | 47 |
| Balloon dilation of esophagus, stomach, and/or upper small bowel using a flexible endoscope, less than 3.0 cm | 44 | 43 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 42 | 42 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Pantoprazole Sodium Other prescribers in San Marcos, TX | 561 |
| Famotidine Other prescribers in San Marcos, TX | 361 |
| Omeprazole Other prescribers in San Marcos, TX | 265 |
| Sucralfate Other prescribers in San Marcos, TX | 76 |
| Esomeprazole Magnesium Other prescribers in San Marcos, TX | 64 |
| Lansoprazole Other prescribers in San Marcos, TX | 56 |
| Peg 3350-Electrolyte (sodium chloride/nahco3/kcl/peg) | 54 |
| Linzess (linaclotide) Other prescribers in San Marcos, TX | 48 |
| Clenpiq (sod picosulf/mag ox/citric ac) | 40 |
| Dicyclomine Hcl Other prescribers in San Marcos, TX | 37 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 23 companies reported 97 payments worth $2,200 in total to this clinician.
| AbbVie Inc. | $538 |
|---|---|
| Echosens North America, Inc. | $223 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $156 |
| Qol Medical, LLC | $152 |
| Janssen Scientific Affairs, LLC | $147 |
| Takeda Pharmaceuticals U.S.A., Inc. | $105 |
| Janssen Biotech, Inc. | $98.10 |
| Phathom Pharmaceuticals, Inc. | $96.81 |
| Food and Beverage | $2,200 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 1 companies. The companies reported $56,255 in research payments for these studies, mostly to the institutions running them.
- A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis
Madrigal Pharmaceuticals · Active, not recruiting · NCT03900429 - A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)
Madrigal Pharmaceuticals · Active, not recruiting · NCT04951219
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.